What is the current Price Target for the Monopar Therapeutics Inc stock?

The average Monopar Therapeutics Inc target price is $43.25. This is 122.94% higher than the current stock price. The highest price target is 369.07%, the lowest is 13.40%. 4 Analysts have issued a price target Monopar Therapeutics Inc 2025 .

How high will the Monopar Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Monopar Therapeutics Inc stock will rise. The performance of stocks, including the Monopar Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Monopar Therapeutics Inc stock today?

The performance of Monopar Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Monopar Therapeutics Inc stock fall?

The decline in Monopar Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Monopar Therapeutics Inc Forecast, price target & analysts

$19.20

1.03% today

Nasdaq, Nov 26, 06:09 pm CET

ISIN

US61023L1089

Symbol

MNPR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Monopar Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Monopar Therapeutics Inc Classifications & Recommendation:

Buy

100%

Monopar Therapeutics Inc Price Target

Target Price	$43.25
Price	$19.40
Potential	122.94% register free of charge
Number of Estimates	4

	4 Analysts have issued a price target Monopar Therapeutics Inc 2025 . The average Monopar Therapeutics Inc target price is $43.25. This is 122.94% register free of charge higher than the current stock price. The highest price target is $91.00 369.07% register free of charge , the lowest is $22.00 13.40% register free of charge .
	A rating was issued by 4 analysts: 4 Analysts recommend Monopar Therapeutics Inc to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Monopar Therapeutics Inc stock has an average upside potential 2025 of 122.94% register free of charge . Most analysts recommend the Monopar Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-3.04	-2.05
	266.27%	32.57%
P/E		negative

The average Monopar Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023.

This results in the following potential growth metrics and future valuations:

2023	$-3.04	266.27%
2024	$-2.05 32.57% Unlock
2025	$-1.40 31.71% Unlock

Current	-9.79	2,176.74%
2024	-9.46 3.37% Unlock
2025	-13.86 46.51% Unlock

Monopar Therapeutics Inc...

Discover more stocks with a high price target

Valneva 309.41%

CureVac N.V. 145.33%

Moderna 70.75%

Bavarian Nordic 68.17%

Alibaba Group Holding Ltd 40.45%

Porsche 39.15%

Teamviewer 37.14%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now